阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AZN 阿斯利康

已收盘 11-06 16:00:00 EST

83.77

+2.62

+3.23%

盘后83.55

-0.22-0.26%

19:53 EST

最高85.02	最低83.37	成交量694.21万
今开84.31	昨收81.15	日振幅2.03%
总市值2,598亿	流通市值2,587亿	总股本31.01亿
成交额5.83亿	换手率0.22%	流通股本30.88亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AZN","market":"US","secType":"STK","nameCN":"阿斯利康","latestPrice":83.77,"timestamp":1762462800000,"preClose":81.15,"halted":0,"volume":6942147,"hourTrading":{"tag":"盘后","latestPrice":83.55,"preClose":83.77,"latestTime":"19:53 EST","volume":170223,"amount":14259056.7639,"timestamp":1762476788069},"delay":0,"floatShares":3088302520,"shares":3101425812,"eps":2.654222,"marketStatus":"已收盘","change":2.62,"latestTime":"11-06 16:00:00 EST","open":84.31,"high":85.02,"low":83.37,"amount":582960407.54976,"amplitude":0.020333,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.654222,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1762506000000},"marketStatusCode":5,"adr":1,"adrRate":0.5,"listingDate":737179200000,"exchange":"NASDAQ","adjPreClose":81.15,"dividendRate":0.018682,"preHourTrading":{"tag":"盘前","latestPrice":84.33,"preClose":81.15,"latestTime":"09:28 EST","volume":202974,"amount":16912717.2117,"timestamp":1762439339972},"postHourTrading":{"tag":"盘后","latestPrice":83.55,"preClose":83.77,"latestTime":"19:53 EST","volume":170223,"amount":14259056.7639,"timestamp":1762476788069},"volumeRatio":1.593147,"impliedVol":0.249,"impliedVolPercentile":0.26},"requestUrl":"/m/hq/s/AZN","defaultTab":"news","newsList":[{"id":"2581097356","title":"美股异动丨阿斯利康涨约3.7%，Q3核心每股盈利超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2581097356","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581097356?lang=zh_cn&edition=full","pubTime":"2025-11-06 23:22","pubTimestamp":1762442530,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2417539215.USD","LU0109394709.USD","BK4585","LU2456880835.USD","AZN","LU0320765992.SGD","LU2462157665.USD","BK4007","LU2236285917.USD","BK4568","LU0889565916.HKD","LU1829250122.USD","BK4588"],"gpt_icon":0},{"id":"2581096749","title":"美股异动 | 阿斯利康(AZN.US)盘前涨逾4% Q3核心每股盈利超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2581096749","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581096749?lang=zh_cn&edition=full","pubTime":"2025-11-06 21:47","pubTimestamp":1762436856,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周四，阿斯利康(AZN.US)盘前涨逾4%，报84.92美元。阿斯利康公布第三季度业绩，总收入同比增长12%至151.91亿美元，核心每股盈利为2.38美元，高于市场预期的2.27美元，受惠于重磅癌症及糖尿病药物销售理想。前九个月收入同比增长10%至432.36亿美元，核心每股盈利为7.04美元。公司重申全年收入将实现高单位数增长，以及核心每股盈利低双位数增长，与市场预期基本一致。公司计划宣布2025年全年股息为每股3.2美元，而去年为3.1美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366293.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2462157665.USD","LU0320765992.SGD","BK4007","AZN","BK4588","LU0109394709.USD","LU2417539215.USD","LU1829250122.USD","LU0889565916.HKD","BK4568","LU2236285917.USD","LU2456880835.USD","BK4585"],"gpt_icon":0},{"id":"2581054856","title":"阿斯利康Q3总收入同比增长12% 核心每股盈利超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2581054856","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581054856?lang=zh_cn&edition=full","pubTime":"2025-11-06 16:37","pubTimestamp":1762418260,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4588","LU2236285917.USD","BK4585","LU0109394709.USD","LU2417539215.USD","LU2462157665.USD","LU1829250122.USD","AZN","BK4568","BK4007","LU2456880835.USD","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2581747059","title":"阿斯利康中国前三季度总营收同比增长5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581747059","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581747059?lang=zh_cn&edition=full","pubTime":"2025-11-06 16:09","pubTimestamp":1762416599,"startTime":"0","endTime":"0","summary":"南方财经11月6日电，2025年前三季度，阿斯利康业绩实现稳健增长。全球总营收同比增长11%，达到432.36亿美元。研发管线进展超过预期，自今年二月以来，阿斯利康已公布16项III期临床试验积极结果，其中5项为新药首次III期数据。与此同时，前三季度阿斯利康中国总营收同比增长5%，达到52.79亿美元，占全球收入的12%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511063557045121.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AZN"],"gpt_icon":0},{"id":"1140094682","title":"阿斯利康第三季度营收与利润超预期，维持全年业绩指引不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1140094682","media":"老虎资讯综合","labels":["dataReport","express"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140094682?lang=zh_cn&edition=full","pubTime":"2025-11-06 15:12","pubTimestamp":1762413159,"startTime":"0","endTime":"0","summary":"得益于核心癌症、心脏病及肾病药物的强劲销售，阿斯利康(AZN)周四盘前公布的第三季度业绩超出预期，该公司因此维持其全年业绩指引不变。消息公布后，阿斯利康夜盘几无变化。","market":"us","thumbnail":"https://community-static.tradeup.com/news/82a8d5a568f404ee362cec1bd92a07d8","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/82a8d5a568f404ee362cec1bd92a07d8"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"阿斯利康第三季度营收与利润超预期，维持全年业绩指引不变","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"gpt_icon":0},{"id":"2581778072","title":"阿斯利康亮相第八届进博会 宣布扩大在华生产布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2581778072","media":"新浪财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581778072?lang=zh_cn&edition=full","pubTime":"2025-11-05 21:47","pubTimestamp":1762350420,"startTime":"0","endTime":"0","summary":"11月5日消息，作为连续八年参展的“全勤生”，跨国药企阿斯利康亮相第八届中国国际进口博览会，并宣布在华扩大生产布局、及在可持续发展方面取得的最新成果，并展出多款创新药物。　　进博首日，阿斯利康与青岛高新技术产业开发区管理委员会签署合作协议，宣布将追加投资约1.36亿美元，用以扩大青岛生产供应基地产能。　　本届进博会上，阿斯利康还首次展出了今年在华获批的两款肿瘤创新药：荃科得和达卓优。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-11-05/doc-infwkiit6396865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2236285917.USD","LU0889565916.HKD","BK4007","LU2417539215.USD","BK4588","LU0109394709.USD","LU2456880835.USD","LU0320765992.SGD","LU1829250122.USD","LU2462157665.USD","BK4585","AZN","BK4568"],"gpt_icon":0},{"id":"2581172555","title":"阿斯利康在青岛追加1.36亿美元投资","url":"https://stock-news.laohu8.com/highlight/detail?id=2581172555","media":"视频滚动新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581172555?lang=zh_cn&edition=full","pubTime":"2025-11-05 19:02","pubTimestamp":1762340520,"startTime":"0","endTime":"0","summary":"11月5日，阿斯利康与青岛高新技术产业开发区管理委员会签署合作协议，宣布将追加投资约1.36亿美元，用以扩大青岛生产供应基地产能。此次扩建将进一步提升阿斯利康吸入气雾剂的产能，更好地满足哮喘、慢阻肺等呼吸系统疾病患者治疗需求。同时，青岛基地项目还采用了节能技术助力实现近零碳运营。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：小浪快报","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/videoroll/2025-11-05/doc-infwkazr4226499.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","BK4585","BK4007","LU0320765992.SGD","LU2462157665.USD","LU0889565916.HKD","LU2456880835.USD","LU0109394709.USD","LU2236285917.USD","BK4568","AZN","LU2417539215.USD","LU1829250122.USD"],"gpt_icon":0},{"id":"2580209167","title":"破局呼吸诊疗，阿斯利康还是太全面了","url":"https://stock-news.laohu8.com/highlight/detail?id=2580209167","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580209167?lang=zh_cn&edition=full","pubTime":"2025-11-04 13:09","pubTimestamp":1762232940,"startTime":"0","endTime":"0","summary":"如何更好地解决呼吸慢病的诊疗难题，成了业界亟需破解的命题。　　在接受媒体采访时，阿斯利康中国总经理、阿斯利康中国生物制药业务总经理林骁道出了阿斯利康连续多年举办“呼吸周”的深意：。　　显然，呼吸周是阿斯利康在中国呼吸治疗领域落子布局的重要抓手。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2025-11-04/doc-infwfiet0114186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1829250122.USD","BK4007","LU0109394709.USD","LU2236285917.USD","LU2417539215.USD","BK4585","LU2456880835.USD","LU0889565916.HKD","BK4588","BK4568","AZN","LU2462157665.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2580260427","title":"展现韧性！欧洲公司对美关税“免疫”，明年有望实现两位数利润增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2580260427","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580260427?lang=zh_cn&edition=full","pubTime":"2025-11-03 15:01","pubTimestamp":1762153273,"startTime":"0","endTime":"0","summary":"智通财经APP注意到，欧洲企业的业绩表明，它们应对美国关税的表现远好于预期——这对明年来说是个好兆头，市场预计其明年将实现两位数的利润增长。汇编数据显示，市场普遍预计明年斯托克600指数成份股公司的每股收益将增长12%。巴克莱周五的一份报告称，文字记录显示，欧盟公司对前景持乐观态度，不太担心关税，并对人工智能效率增益持积极态度。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251103150618a6dd32ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251103150618a6dd32ec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","BK4007","LU2417539215.USD","AZN","LU0109394709.USD","LU1829250122.USD","LU2236285917.USD","LU2462157665.USD","LU2456880835.USD","LU0889565916.HKD","BK4585","BK4588","LU0320765992.SGD"],"gpt_icon":0},{"id":"2578987562","title":"构建多元化合作模式 和铂医药-阿斯利康北京创新实验室揭牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2578987562","media":"新京报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578987562?lang=zh_cn&edition=full","pubTime":"2025-10-28 15:32","pubTimestamp":1761636751,"startTime":"0","endTime":"0","summary":"10月25日，和铂医药-阿斯利康创新实验室在北京正式揭牌，和铂医药北京创新中心同步揭牌。据了解，截至目前，和铂医药的抗体技术平台已与阿斯利康、辉瑞、大冢、艾伯维、莫德纳等多家跨国药企达成合作，累计总金额超百亿美元，并获得阿斯利康溢价入股，以及新加坡政府投资公司（GIC）增持股份至7.05%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510283546756820.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510283546756820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","LU0109394709.USD","BK4568","BK1574","BK4585","LU2417539215.USD","LU2456880835.USD","AZN","LU0320765992.SGD","BK1583","LU2462157665.USD","BK4007","LU2236285917.USD","02142","LU0889565916.HKD","LU1829250122.USD","BK4588"],"gpt_icon":0},{"id":"2578349629","title":"从授权合作迈向生态共建：阿斯利康持续加码，赋能中国生物医药创新","url":"https://stock-news.laohu8.com/highlight/detail?id=2578349629","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578349629?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:13","pubTimestamp":1761563636,"startTime":"0","endTime":"0","summary":"在此合作模式之下，中英两国在医药健康领域的合作有望进入新阶段。推动生态共建为进一步强化研发实力，阿斯利康还与和铂医药启动在肿瘤及自身免疫性疾病领域的研究合作。一个用于开展研究合作的全新创新实验室于同日正式启用，毗邻阿斯利康全球研发北京战略中心。阿斯利康国际业务拓展合作与战略投资副总裁陈冰表示，此次与和铂医药的合作是阿斯利康赋能本土创新的重要表现。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251027194940a6d0beb7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251027194940a6d0beb7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","AZN","BK4588","LU2456880835.USD","LU0109394709.USD","LU2236285917.USD","BK4585","BK4007","LU2417539215.USD","LU0889565916.HKD","LU1829250122.USD","LU2462157665.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2578662588","title":"港股异动 | 和铂医药-B(02142)涨超6% 与阿斯利康进一步深化合作 AI干湿实验室平台即将正式投入使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2578662588","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578662588?lang=zh_cn&edition=full","pubTime":"2025-10-27 09:51","pubTimestamp":1761529911,"startTime":"0","endTime":"0","summary":"据介绍，今年3月，和铂医药与阿斯利康达成全球战略合作，共同研发针对免疫性疾病、肿瘤及其他多种疾病的新一代多特异性抗体疗法，并在北京建设创新实验室，推动前沿科研落地。经过数月筹备，该创新实验室全面就绪，和铂医药抗体药物创新开发平台与AI干湿实验室平台已完成搭建，即将正式投入使用，助力多领域新一代治疗性抗体研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1360185.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1829250122.USD","BK1574","BK4007","BK1583","LU0109394709.USD","LU2236285917.USD","LU2417539215.USD","BK4585","LU2456880835.USD","LU0889565916.HKD","BK1161","AZN","BK4588","BK4568","02142","LU2462157665.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2576831272","title":"阿斯利康(AZN.US)乳腺癌药物Enhertu预防复发效果优于竞品 有望治愈早期患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2576831272","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576831272?lang=zh_cn&edition=full","pubTime":"2025-10-20 16:50","pubTimestamp":1760950241,"startTime":"0","endTime":"0","summary":"据阿斯利康称，在早期阶段疾病中获得批准可能会使该药物惠及八国集团中另外约 13 万名患者。在一项研究中，接受Enhertu治疗的患者中有超过 92% 在术后三年仍存活且无侵袭性疾病，而接受Kadcyla治疗的患者这一比例为 84%。在接受Enhertu治疗的患者中，约三分之二的患者在手术时其乳腺或淋巴结中的癌细胞已完全消失，而标准治疗组这一比例为 56%。使用Enhertu治疗的患者还表示出现了更少的严重副作用。不过，他指出，手术后使用Enhertu的疗效是明确的。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1357075.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"阿斯利康(AZN.US)乳腺癌药物Enhertu预防复发效果优于竞品 有望治愈早期患者","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","BK4568","LU0109394709.USD","LU2456880835.USD","AZN","LU2417539215.USD","BK4585","LU0320765992.SGD","LU2236285917.USD","LU1829250122.USD","LU2462157665.USD","LU0889565916.HKD","BK4588"],"gpt_icon":0},{"id":"2576055960","title":"药品量身定制？透视3D打印风口背后的挑战与机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2576055960","media":"医药经济报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576055960?lang=zh_cn&edition=full","pubTime":"2025-10-19 09:04","pubTimestamp":1760835881,"startTime":"0","endTime":"0","summary":"在制药行业，以3D打印、人工智能、器官芯片为代表的前沿技术，正从药物发现、临床试验到个性化生产全链条，为创新药研发注入前所未有的动能。3D打印还可通过内部结构设计实现药物的定点与持续释放，显著提升局部生物利用度。现行药品审评体系主要针对标准化批量生产，难以评估3D打印药物特有的质量属性，如内部结构精度、层间结合力和药物分布均匀性。整体来看，3D打印药物在技术、生产模式和监管三个维度正逐步成熟。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251019091007a4673316&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251019091007a4673316&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","LU2236285917.USD","BK4588","LU0320765992.SGD","LU2456880835.USD","BK4585","LU2417539215.USD","LU2462157665.USD","BK4007","AZN","LU0109394709.USD","LU1829250122.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2575994746","title":"德银质疑阿斯利康(AZN.US)关键乳腺癌药物前景 罕见给予“卖出”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2575994746","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575994746?lang=zh_cn&edition=full","pubTime":"2025-10-16 20:25","pubTimestamp":1760617511,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，德意志银行分析师周四给予阿斯利康\"卖出\"评级，对该英国制药商的药物研发管线持更为审慎的看法。帕帕达基斯在报告中写道，\"随着阿斯利康股价升至近期交易区间高位，我们借此机会转向更明确的看空，\"他上一次对该股给出\"买入\"建议是在2023年7月。该分析师认为，阿斯利康的关键乳腺癌药物camizestrant不太可能展现出比同类药物更显著的疗效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"德银质疑阿斯利康(AZN.US)关键乳腺癌药物前景 罕见给予“卖出”评级","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AZN"],"gpt_icon":0},{"id":"2575244159","title":"手握阿斯利康重磅交易，国产减肥药“黑马”冲击港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2575244159","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575244159?lang=zh_cn&edition=full","pubTime":"2025-10-14 20:19","pubTimestamp":1760444373,"startTime":"0","endTime":"0","summary":"一家手握重磅BD的生物医药企业，正在冲刺港股。10月8日，诚益生物向港交所提交上市申请。港交所上市环境更宽松，诚益生物赴港敲钟的进展显然就能更快。ECC5004有望成为同类最佳，并且是第二个在全球上市的口服小分子GLP-1受体激动剂。10月13日，石药集团的依达格鲁肽α注射液的新药上市申请已获得国家药监局受理，适应症为减重。诚益生物的品种还在研发之中，根据协议，阿斯利康会和诚益生物共同开发和商业化ECC5004。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014210406a45fa2a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014210406a45fa2a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2461242641.AUD","LU2236285917.USD","LU2750360641.GBP","01801","GB00BDT5M118.USD","LU2462157665.USD","BK4581","AZN","LU0432979614.USD","03933","IE00B1BXHZ80.USD","LU2237438978.USD","LU0820561909.HKD","LU0708995401.HKD","IE0004445239.USD","LU0354030438.USD","SG9999015945.SGD","LU0256863902.USD","LU2491050071.SGD","LU0823434583.USD","BK4516","LU0385154629.USD","BK4534","LU0823434740.USD","LU2361044949.HKD","SG9999001176.USD","LU0238689110.USD","LU1023059063.AUD","BK4588","LU1548497426.USD","LU2237443622.USD","IE00B2B36J28.USD","LU0882574055.USD","SGXZ81514606.USD","LU2112291526.USD","01093","SG9999014914.USD","LU1232071149.USD","LU2089984988.USD","SGXZ31699556.SGD","LU2360106947.USD","LU1057294990.SGD","LU2456880835.USD","LU2491050154.USD","SG9999017495.SGD","LU2237443978.SGD","LU0689472784.USD","LU0256863811.USD","BK4599","LU0198837287.USD","LU2471134523.USD","LU0889565916.HKD"],"gpt_icon":1},{"id":"2575427867","title":"阿斯利康将携四项重磅研究首发数据亮相欧洲肿瘤内科学会年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2575427867","media":"动脉网","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575427867?lang=zh_cn&edition=full","pubTime":"2025-10-14 19:46","pubTimestamp":1760442360,"startTime":"0","endTime":"0","summary":"欧洲肿瘤内科学会年会将于2025年10月17日至21日召开，阿斯利康将携逾95项摘要亮相，涵盖9款获批药物及9款潜在新药，包括2项入选重磅主席研讨会摘要及26项口头报告。阿斯利康全球执行副总裁高书璨表示，将公布多项研究数据和进展，展示新一代潜在抗肿瘤新药。肿瘤业务负责人Dave Fredrickson称，公司肿瘤产品组合持续展现强劲势头，首次公布四项关键研究数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101420051894c8ac6f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101420051894c8ac6f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1829250122.USD","BK4585","AZN","LU0889565916.HKD","LU0320765992.SGD","BK4007","BK4568","LU2417539215.USD","LU0109394709.USD","LU2236285917.USD","BK4588","LU2462157665.USD","LU2456880835.USD"],"gpt_icon":0},{"id":"2575627899","title":"云顶新耀EVM14中美双获批，艾伯维新药报产，和美药业新药上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2575627899","media":"医药经济报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575627899?lang=zh_cn&edition=full","pubTime":"2025-10-14 18:11","pubTimestamp":1760436664,"startTime":"0","endTime":"0","summary":"云顶新耀EVM14中美双获批10月13日，专注于创新疗法的发现、临床开发、生产和商业化的生物制药公司云顶新耀宣布，其肿瘤相关抗原肿瘤疫苗EVM14的新药临床试验申请已获得NMPA的批准。此前，EVM14新药临床试验申请于2025年3月获FDA批准。此次获批的I期临床试验主要目的是观察EVM14的安全性和耐受性，次要目的是观察其疗效。在EVM14 I期临床试验探索的瘤种中，大多数患者会表达5个TAA之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014200833a6b8f5b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014200833a6b8f5b5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VTRS","LU0889565916.HKD","LU2236285917.USD","LU1223082196.USD","LU1223083913.SGD","BK4588","AZN","LU2417539215.USD","LU2462157665.USD","BK4568","BK4007","LU0109394709.USD","CDE","LU0320765992.SGD","LU1829250122.USD","BK4585","LU2456880835.USD","BK4017","LU1223082519.USD"],"gpt_icon":0},{"id":"2575726014","title":"降价协议换得三年关税豁免期 大摩给予阿斯利康(AZN.US)“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2575726014","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575726014?lang=zh_cn&edition=full","pubTime":"2025-10-14 17:10","pubTimestamp":1760433022,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根士丹利表示，阿斯利康与美国政府就关税和药品定价达成的公告可能带来缓解，推动该行业情绪进一步改善。该行给予阿斯利康“增持”评级，目标价137英镑。当地时间10月10日，美国总统特朗普宣布，其政府已与阿斯利康达成协议，后者将大幅削减部分药品的消费者价格以换取关税宽限待遇。阿斯利康宣布了一项与辉瑞类似的协议，这表明美国政府有意维护该行业的基本面。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1354825.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"降价协议换得三年关税豁免期 大摩给予阿斯利康(AZN.US)“增持”评级","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AZN"],"gpt_icon":0},{"id":"2575278675","title":"IPO日报-阿斯利康是唯一客户，这家药企申请上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2575278675","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575278675?lang=zh_cn&edition=full","pubTime":"2025-10-14 15:02","pubTimestamp":1760425373,"startTime":"0","endTime":"0","summary":"IPO日报注意到，这家公司目前仍处于临床阶段，尚无商业化产品，但手握多条口服小分子代谢管线，背后更是有阿斯利康“站台”持股。这些收入均来自阿斯利康这唯一一个客户，这也导致诚益生物的财务表现出现较大波动，公司2023年亏损，2024年扭亏为盈，达到1.39亿美元，但今年上半年公司再次亏损，主要原因是从阿斯利康收取的很大一部分预付款被确认为2024年的收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014150326a45f110c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014150326a45f110c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4007","LU2456880835.USD","LU2462157665.USD","BK4568","AZN","LU2417539215.USD","LU2236285917.USD","LU0320765992.SGD","LU0889565916.HKD","LU1829250122.USD","LU0109394709.USD","BK4588"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":-0.0131},{"period":"1month","weight":-0.0508},{"period":"3month","weight":0.0882},{"period":"6month","weight":0.201},{"period":"1year","weight":0.2245},{"period":"ytd","weight":0.2386}],"compareEarnings":[{"period":"1week","weight":-0.0143},{"period":"1month","weight":0.0089},{"period":"3month","weight":0.0717},{"period":"6month","weight":0.2007},{"period":"1year","weight":0.1749},{"period":"ytd","weight":0.1561}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.001428},{"month":2,"riseRate":0.40625,"avgChangeRate":-0.017129},{"month":3,"riseRate":0.5625,"avgChangeRate":0.027992},{"month":4,"riseRate":0.65625,"avgChangeRate":0.031251},{"month":5,"riseRate":0.53125,"avgChangeRate":0.008752},{"month":6,"riseRate":0.454545,"avgChangeRate":0.018335},{"month":7,"riseRate":0.606061,"avgChangeRate":-0.002513},{"month":8,"riseRate":0.484848,"avgChangeRate":0.004788},{"month":9,"riseRate":0.545455,"avgChangeRate":0.001232},{"month":10,"riseRate":0.545455,"avgChangeRate":0.015301},{"month":11,"riseRate":0.484848,"avgChangeRate":-0.000491},{"month":12,"riseRate":0.5625,"avgChangeRate":0.007964}],"exchange":"NASDAQ","name":"阿斯利康","nameEN":"AstraZeneca PLC"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.5","shortVersion":"4.35.5","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康,AZN,阿斯利康股票,阿斯利康股票老虎,阿斯利康股票老虎国际,阿斯利康行情,阿斯利康股票行情,阿斯利康股价,阿斯利康股市,阿斯利康股票价格,阿斯利康股票交易,阿斯利康股票购买,阿斯利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}